Search results for: 'spectrometry machine learning'

22 Jan 2021  |  Global  |  Market Research

Leveraging Vertical and IoT Expertise Improves Outcomes for the Global IoT-Managed Services Market

Everything-as-a-Service (XaaS) Model Widens Adoption Options to Enhance Customer Experience

Infographics

×

Key Issues Addressed

While Internet of Things (IoT) adoption is a strategic imperative, companies struggle with legacy infrastructure, connectivity, and implementation decisions. IoT providers can help companies advance IoT plans by using their expertise and portfolio of solutions. Instead of following a build-and-own approach, companies should opt for IoT-managed serv...

23 Apr 2021  |  Global  |  Market Research

Global Workforce IAM—Disruptive Technologies and Unified Access Solutions Enable Robust Security Postures

Enterprises Benefit from Vendor Focus on Reducing IAM Complexity to Enhance User Experience

Infographics

×

Key Issues Addressed

As part of Frost & Sullivan’s ongoing research on cybersecurity, we conducted a deep-dive analysis of the Workforce Identity and Access Management (IAM) market. Frost & Sullivan defines Workforce IAM as a framework that controls and manages employee identities and access as well as policies across IT infrastructures, to protect enterprises from una...

While Internet of Things (IoT) adoption is a strategic imperative, companies struggle with decisions related to legacy infrastructures, connectivity architecture and implementation. IoT professional service providers can help companies advance IoT plans by using their expertise and portfolio of solutions. Instead of following a build-and-own approa...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...

14 Jul 2017  |  North America  |  Market Research

Gamification in the Automotive Industry, Forecast to 2025

The Global Gamification Market will Reach $14.5 Billion in 2025

Infographics

×

Gamification technologies help businesses to drive sales, improve return on investment (ROI), support employee interaction, and provide high customer satisfaction, and they are preferred across major industry verticals such as healthcare and automotive. The increasing penetration of smartphones, customized services, tech-savvy customers, the growin...

This research service is part of Frost & Sullivan's Integrated Commerce Research Programme. It provides an original perspective on how artificial intelligence (AI) is making its way into the retail sector. Retail has entered a new era where eCommerce and technology bellwethers like Alibaba, Amazon, Apple, Baidu, Facebook, Google, Microsoft, and Ten...

The need for innovation is driving growth in disruptive business models. Traditional industries such as transportation, housing, delivery, finance, and banking have been challenged by new entrants with disruptive business structures which are challenging the old regulatory rules that previously governed the markets. Emerging technologies such as AI...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....